| Not Yet Recruiting | Tumor Budding and T1 Substaging in Urothelial Bladder Cancer NCT07529639 | Assiut University | — |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer NCT07067749 | University of Rome Tor Vergata | Phase 3 |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | The Vanguard Study: Testing a New Way to Screen for Cancer NCT06995898 | National Cancer Institute (NCI) | N/A |
| Recruiting | Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy NCT06891209 | Mayo Clinic | — |
| Recruiting | PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808 | Var2 Pharmaceuticals | EARLY_Phase 1 |
| Withdrawn | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N NCT05564416 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Vaccine Response With NT-I7 NCT04054752 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers a NCT05819827 | Mayo Clinic | — |
| Recruiting | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary C NCT05519878 | City of Hope Medical Center | N/A |
| Unknown | EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy NCT05480735 | The Netherlands Cancer Institute | N/A |
| Recruiting | Bladder Bank (a Prospective Banking Study) NCT06109857 | Mayo Clinic | — |
| Terminated | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours NCT05363605 | Fusion Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Completed | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Usin NCT06789224 | Lindis Bloodcare GmbH | N/A |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Completed | Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy NCT04502095 | Roswell Park Cancer Institute | Phase 4 |
| Active Not Recruiting | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers NCT04459273 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Unknown | Patient-Derived Xenografts to Reduce Cancer Health Disparities NCT04410302 | University of California, Davis | — |
| Unknown | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" NCT03824691 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer NCT05399004 | Mayo Clinic | — |
| Terminated | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms NCT03549650 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 2 |
| Active Not Recruiting | Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery NCT03757949 | SWOG Cancer Research Network | Phase 3 |
| Withdrawn | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cance NCT02438852 | University of Southern California | Phase 3 |
| Terminated | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma NCT03324282 | University Hospital, Bordeaux | Phase 2 |
| Completed | TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer NCT03125226 | University of Washington | N/A |
| Completed | The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surg NCT03064308 | University of Nottingham | N/A |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Terminated | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy NCT02145390 | University of Miami | N/A |
| Completed | PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) NCT02439060 | University of Southern California | N/A |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer a NCT02408406 | City of Hope Medical Center | N/A |
| Completed | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystect NCT02355886 | University of Washington | Phase 2 / Phase 3 |
| Unknown | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Mali NCT02457650 | Shenzhen Second People's Hospital | Phase 1 |
| Terminated | Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection NCT02202044 | University of Colorado, Denver | N/A |
| Terminated | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery NCT02169284 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy NCT01245660 | University Hospital, Bordeaux | EARLY_Phase 1 |
| Terminated | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma NCT01215136 | Matthew Galsky | Phase 2 |
| Completed | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) NCT00753415 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Cone Beam CT Scanning in Lung and Bladder Cancer. NCT00469066 | AHS Cancer Control Alberta | — |